Strides Pharma Science · NSE: STAR · BSE: 532531

Q1 FY22 results · Apr–Jun 2021

Strides Pharma Science reported revenue from operations of ₹688.37 crore (down 12.0% from Q1 FY21) and net loss of ₹208.57 crore for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY22	Q1 FY21	YoY	Q4 FY21	QoQ
Revenue from operations	688.37	781.80	−12.0%	908.49	−24.2%
Other income	13.53	12.30	+10.0%	13.05	+3.7%
Total income	701.90	794.10	−11.6%	921.54	−23.8%
Profit before share of associates & JVs and tax	(224.58)	126.08	Turned loss	75.89	Turned loss
Share of profit/(loss) of associates & JVs	(19.53)	(20.96)		(19.82)
Net profit for the period	(208.57)	101.84	Turned loss	43.74	Turned loss
Attributable to shareholders of the company	(205.20)	103.56	Turned loss	46.09	Turned loss
EPS, basic (₹)	(22.88)	11.56	Turned loss	5.14	Turned loss
Net margin (%)	-30.3	13.0		4.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY22	Q1 FY21	YoY	Q4 FY21	QoQ
Revenue from operations	508.79	409.34	+24.3%	633.60	−19.7%
Other income	8.75	15.33	−42.9%	23.31	−62.5%
Total income	517.54	424.67	+21.9%	656.90	−21.2%
Profit before tax	(27.79)	6.14	Turned loss	68.69	Turned loss
Net profit for the period	(21.23)	4.16	Turned loss	48.08	Turned loss
EPS, basic (₹)	(2.37)	0.46	Turned loss	5.36	Turned loss
Net margin (%)	-4.2	1.0		7.6

Consolidated

Filed with BSE: 06 Aug 2021, 17:54 IST
Board meeting: 06 Aug 2021
Period: 01 Apr 2021 to 30 Jun 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 06 Aug 2021, 17:54 IST
Board meeting: 06 Aug 2021
Period: 01 Apr 2021 to 30 Jun 2021
Review status: Unaudited
Source: XBRL filing on BSE